Skip to main
ACON

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion is a healthcare technology company with a positive outlook, driven by recent commercial agreements with Weill Cornell Medicine and Och Spine, as well as the appointment of a Commercial Director, Western US. Despite relatively nominal revenues in Q4 FY25, the company saw an 81% increase in revenue Yoy and rising Nociscan scan volume, with an expected CLARITY trial data readout in Q3 2026. With a strong balance sheet and potential for significant market opportunity, Aclarion's stock has potential for growth, despite the risks of balance sheet/liquidity, regulatory approvals, and competition.

Bears say

Aclarion is facing difficulties with share count expansion, with a significant increase to 2.3 million shares from 670 thousand last quarter. This has resulted in a decrease in the 12-month price target to $7.00 (from $23.00). Despite this, the company's net cash per share is currently sitting at $17 and the commercialization of Nociscan is expected to bring in significant revenue, although slower adoption from surgeons and higher expenses could present risks to the overall thesis.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.